Premium
Evaluation and application of donors with primary central nervous system tumors
Author(s) -
Wu JiHua,
Qiao PengFei,
Sun XuYong,
Dong JianHui,
Liao JiXiang,
Liu XuYang,
Gao Zhao,
Lan LiuGen,
Li HaiBin,
Su QingDong
Publication year - 2019
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13677
Subject(s) - medicine , incidence (geometry) , metastasis , donation , liver transplantation , kidney , survival rate , surgery , primary tumor , oncology , transplantation , cancer , physics , optics , economics , economic growth
Abstract Background This study aimed to explore the safety of donors with primary central nervous system tumors for kidney and liver transplantations. Methodology Clinical data of 29 donors with primary CNS tumors in January 2007 to December 2017, as well as the follow‐up data of 16 liver transplant recipients and 46 kidney transplant recipients, were analyzed. According to the risk factors, the high‐risk group was classified as Group 1, the low‐risk factors were classified as Group 2, and the unknown risk group was classified as Group 3. The incidence of donor‐transmitted CNS tumors was calculated and compared. Results The duration from the diagnosis of 29 donors to donation was 5.67 ± 6.36 months. None of the liver and kidney transplant recipients who were followed up had tumor metastasis. Although the mean survival time of Group 1 was lower than that of Group 2 and Group 3, the Kaplan‐Meier curve showed no significant difference in survival time. Conclusion No obvious difference was observed between high‐risk and low‐risk and unknown risk CNS tumors in terms of the survival rate of transplants and tumor metastasis rate. High‐risk CNS tumor donors can be used with the informed consent of recipients after a full evaluation.